InnoCan Pharma Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Iris Or Gabi Bincovich
- Full Time Employees
- 11
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1015, 926 – 5 Avenue SW Calgary AB Canada T2P 0N7
- IPO Date
- Sep 25, 2019
- Website
- innocanpharma.com
- Similar Companies
- Business
- InnoCan Pharma Corporation is a pharmaceutical technology company specializing in the development of innovative drug delivery platforms that combine cannabidiol (CBD) with other pharmaceutical ingredients. Its primary products include the LPT-CBD liposome platform, designed for precise dosing and prolonged, controlled release of synthetic CBD for non-opioid pain management, targeting indications such as epilepsy and chronic pain. Additionally, the company develops and markets a broad portfolio of high-performance self-care and beauty products under its consumer wellness segment, leveraging advanced online sales channels through its subsidiary BI Sky Global Ltd. InnoCan Pharma operates internationally in the United States, Canada, Europe, and beyond, with headquarters located in Alberta, Canada. Founded in 2017, the company also conducts research in collaboration with academic institutions like Tel Aviv University and Hebrew University of Jerusalem on cannabinoid-loaded exosome delivery systems for CNS conditions and other therapeutic uses. Recent significant developments include advancing the LPT-CBD drug delivery platform toward regulatory approval with the U.S. FDA, including preclinical studies supporting its safety and efficacy for sustained pain relief. The company has initiated the FDA approval process for its liposomal CBD injection therapy aimed at chronic pain, a critical step toward clinical trials and commercialization. InnoCan Pharma also expanded its intellectual property portfolio, securing patents such as the LPT-CBD liposomal injection technology in Japan. Strategically, it formed partnerships like the research and license agreement with Ramot, the technology transfer company of Tel Aviv University, to develop a revolutionary cannabinoids-loaded exosome delivery platform. Furthermore, InnoCan collaborates with organizations such as Freedom Farm, a sanctuary for injured animals, to apply its LPT-CBD technology for veterinary analgesic use, demonstrating its commitment to broad therapeutic impact. The company completed private placements raising multimillion-dollar investments to support ongoing R&D and commercialization efforts. These initiatives underscore Innocan Pharma's dual focus on developing cutting-edge pharmaceutical technologies and delivering health and wellness consumer products globally.
Company News
VALITIC™ Expands Retail Industry Visibility Through Shoptalk Fall 2026 in Nashville, USA
Innocan Pharma Announces Private Placement of Units
Over 100,000 Positive Verified Customer Reviews Reflect Growing Consumer Trust
Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M
Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest
Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M
Innocan Pharma to Present at the 2024 ThinkEquity Conference
Innocan Pharma to Present at the 2024 ThinkEquity Conference
Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million
Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Innocan Pharma Corporation Closes C$8.2 Million Private Placement with Institutional Investors
Innocan Pharma Corporation Announces C$8.2 Million Private Placement with Institutional Investors
Innocan Pharma Announces the Filing of a PCT Patent Application for its CBD Delivery System Technology in 153 Countries
Innocan Pharma Announces the Filing by Ramot at Tel Aviv University of an International Patent Application for its Unique Cannabinoids Loaded Exosome Delivery Platform (CLX)
Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals